Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,340.00
Bid: 12,360.00
Ask: 12,362.00
Change: -76.00 (-0.61%)
Spread: 2.00 (0.016%)
Open: 12,234.00
High: 12,370.00
Low: 12,164.00
Prev. Close: 12,416.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-SAP drags down German shares, COVID-19 worries weigh on broader Europe

Mon, 26th Oct 2020 09:43

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* German DAX closes at lowest in almost 4 months

* SAP cutting its 2020 outlook, posts worst fall in 24 years

* SAP's pessimism dents hopes of global recovery - analyst

* Oil drop pressures energy stocks
(Updates to close)

By Sruthi Shankar and Susan Mathew

Oct 26 (Reuters) - German shares closed at their lowest in
nearly four months on Monday as Europe's most valuable tech
firm, SAP, experienced its worst trading day in 24
years after cutting its 2020 outlook.

The German DAX fell 3.7% as SAP slumped
almost 22% after abandoning medium-term profitability targets
and cautioning that its business would take longer than expected
to recover from the pandemic hit.

"SAP's pessimism does not bode well for hopes for the global
economic recovery to continue," said Edward Moya, senior market
analyst at OANDA, New York.

"If tech goes, the deteriorating outlook due to virus spread
will likely yield massive risk aversion as investors head for
the sidelines instead of rotating into cyclicals."

The wider European tech index slid 7.4%.

SAP's results came as a blip in the third-quarter earnings
season, which has been largely better than feared.

Meanwhile, fresh COVID-19-induced restrictions in Italy and
Spain to curb a resurgence in cases weighed on the rest of
Europe, with the pan-European STOXX 600 index closing
at a one-month low, down 1.8%.

Europe on Saturday became the second region after Latin
America to surpass 250,000 deaths, according to a Reuters tally.

The euro zone blue-chip index fell nearly 3%,
while Europe's travel and leisure sector, worst hit by the
movement curbs, was down 3.3%.

Nick Nelson, head of European equity strategy at UBS, said
the Swiss bank's target for STOXX 600 into the year-end is 340
points, about 4.5% below the current level, in part due to the
impact of the latest round of restrictions.

Surveys of euro zone purchasing managers last week showed
economic activity slipped back into decline in October,
heightening expectations for a double-dip recession as a second
wave of virus sweeps across the continent.

Globally, risk appetite was sapped by worries over slow
progress on a new U.S. stimulus bill and a looming presidential
election.

Milan's blue-chip index fell 1.8% even as ratings
agency Standard and Poor's upgraded Italy's sovereign outlook to
stable from negative.

Oil majors Total and Royal Dutch Shell
fell over 2.8% as crude prices slumped more than 3% on demand
worries.

Healthcare stocks remained supportive, with
AstraZeneca gaining 1.7% after it resumed the U.S. trial
of its experimental COVID-19 vaccine.

French stocks dipped 1.9%. Turkish leader Tayyip
Erdogan asked his compatriots to stop buying French goods on
Monday in the latest expression of anger in the Muslim world
over images being displayed in France of the Prophet Mohammad,
which some Muslims consider blasphemous.
(Reporting by Sruthi Shankar in Bengaluru; Editing by Sriraj
Kalluvila and Emelia Sithole-Matarise)

More News
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more
29 Aug 2023 12:33

US government names first 10 drugs for Medicare price negotiation

Aug 29 (Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program.

Read more
29 Aug 2023 11:00

US to name first 10 drugs for Medicare price negotiation

Aug 29(Reuters) - The Biden administration on Tuesday is expected to release its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people.

Read more
25 Aug 2023 11:59

Novo says Wegovy drug helps obese people with heart failure in trial

Aug 25 (Reuters) - Novo Nordisk said its hugely popular drug Wegovy was shown to substantially ease heart failure in obese people, as the Danish drugmaker seeks to further build its case for the medicine's health benefits beyond weight loss.

Read more
24 Aug 2023 16:24

UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Thursday jointly said its Lynparza treatments have been approved in Japan.

Read more
24 Aug 2023 08:25

AstraZeneca says Soliris and Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC on Thursday said both its Soliris and Lynparza treatments have been approved in Japan.

Read more
23 Aug 2023 16:15

AstraZeneca facing two London lawsuits over COVID-19 vaccines

LONDON, Aug 23 (Reuters) - AstraZeneca is facing two London lawsuits, including one from the husband of a woman who died after receiving the Anglo-Swedish drugmaker's COVID-19 vaccine, in the first of potentially dozens of cases brought in England.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more
23 Aug 2023 07:42

Daiichi Sankyo and AstraZeneca's Enhertu wins new approval in Japan

(Alliance News) - AstraZeneca PLC's partner Daiichi Sankyo Co Ltd on Wednesday announced that their cancer drug Enhertu has received another approval in Japan.

Read more
22 Aug 2023 06:06

Pay for FTSE 100 bosses jumps 16% as wider wages behind inflation

(Alliance News) - The bosses of Britain's biggest companies saw their pay surge by 16% last year as most workers saw their pay packets outstripped by inflation, according to new research.

Read more
21 Aug 2023 22:37

US FDA approves Pfizer's maternal RSV vaccine to protect infants

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Read more
21 Aug 2023 20:56

Britain's CEOs get 16% pay rise to 3.9 mln pounds even as workers struggle

LONDON, Aug 21 (Reuters) - The bosses of Britain's biggest companies saw their pay jump 16% in 2022, sending their average earnings to 118 times the median UK full-time worker's while employees struggled with soaring inflation, new research showed on Monday.

Read more
21 Aug 2023 07:45

AstraZeneca hails new data on Forxiga's impact on heart failure

(Alliance News) - AstraZeneca PLC on Monday announced that new data from its studies show positive effects of Forxiga on people with heart failure.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.